Thomas R. Caferro

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

Young Shin Cho, Julian Levell, Gang Liu et al. · ACS Medicinal Chemistry Letters · 2017 · 118 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +7

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Edgar R. Wood, Lisa M. Shewchuk, Byron Ellis et al. · Proceedings of the National Academy of Sciences · 2008 · 112 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +13

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Tara Rheault, Thomas R. Caferro, Scott H. Dickerson et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 83 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Antimalarial sulfone trioxanes

Gary H. Posner, Hardwin O’Dowd, Thomas R. Caferro et al. · Tetrahedron Letters · 1998 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

4-Alkyl- and 3,4-dialkyl-1,2,3,4,-tetrahydro-8-pyridono[5,6-g]quinolines: Potent, nonsteroidal androgen receptor agonists

Robert I. Higuchi, James P. Edwards, Thomas R. Caferro et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 52 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12